Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12–24 months
Open Access
- 17 July 2009
- journal article
- research article
- Published by Springer Nature in Malaria Journal
- Vol. 8 (1) , 163
- https://doi.org/10.1186/1475-2875-8-163
Abstract
Development and deployment of an effective malaria vaccine would complement existing malaria control measures. A blood stage malaria vaccine candidate, Merozoite Surface Protein-3 (MSP3), produced as a long synthetic peptide, has been shown to be safe in non-immune and semi-immune adults. A phase Ib dose-escalating study was conducted to assess the vaccine's safety and immunogenicity in children aged 12 to 24 months in Korogwe, Tanzania (ClinicalTrials.gov number: NCT00469651).Keywords
This publication has 22 references indexed in Scilit:
- A new global malaria eradication strategyThe Lancet, 2008
- Long-Term Clinical Protection from Falciparum Malaria Is Strongly Associated with IgG3 Antibodies to Merozoite Surface Protein 3PLoS Medicine, 2007
- Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthethic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West AfricaVaccine, 2007
- Levels of Plasma Immunoglobulin G with Specificity against the Cysteine-Rich Interdomain Regions of a SemiconservedPlasmodium falciparumErythrocyte Membrane Protein 1, VAR4, Predict Protection against Malarial Anemia and Febrile EpisodesInfection and Immunity, 2006
- A Malaria Vaccine That Elicits in Humans Antibodies Able to Kill Plasmodium falciparumPLoS Medicine, 2005
- Association of Transmission Intensity and Age With Clinical Manifestations and Case Fatality of Severe Plasmodium falciparum MalariaJAMA, 2005
- The global distribution of clinical episodes of Plasmodium falciparum malariaNature, 2005
- Association between Protection against Clinical Malaria and Antibodies to Merozoite Surface Antigens in an Area of Hyperendemicity in Myanmar: Complementarity between Responses to Merozoite Surface Protein 3 and the 220-Kilodalton Glutamate-Rich ProteinInfection and Immunity, 2004
- Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages.The Journal of Experimental Medicine, 1995
- Antibodies in falciparum malaria: what matters most, quantity or quality?Memórias do Instituto Oswaldo Cruz, 1992